Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-Current Deffered Revenue (2018)

Northwest Biotherapeutics (NWBO) has 1 years of Non-Current Deffered Revenue data on record, last reported at $4.8 million in Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue changed N/A year-over-year to $4.8 million; the TTM value through Dec 2018 reached $4.8 million, changed N/A, while the annual FY2018 figure was $4.8 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $4.8 million in Q4 2018 per NWBO's latest filing.
  • Across five years, Non-Current Deffered Revenue topped out at $4.8 million in Q4 2018 and bottomed at $4.8 million in Q4 2018.